tbuckley/cabot-search huggingface dataset:
Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?
Authors: Bruno Vincenzi, Anna Maria Frezza, Giuseppina Maltese, Linda Cerbone, Delia Delisi, Marianna Silletta, Mariella Spalato Ceruso, Giuseppe Badalamenti, Daniele Santini, Giuseppe Tonini
Journal: Journal of Clinical Oncology (2014)

10572 Background: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastatic disease or locally advanced inoperable and received at least one previous line of treatment containing anthracycline. All patients received standard steroids premedication. Results: Median age was 57 years (range: 27-79 ys) and male/female ratio was 71/42. STS histologies were: liposarcoma 32 cases, leiomeiosarcoma 27, pleomorphic sarcoma 17, synovial sarcoma 13, 24 other histologies. For 45 patients a G3-4 ALT increase in the first two cycles was reported while for 68 was not. Calculations show that hazard ratios for PFS and OS are not statistically significant (HR=1.124; p=0.734 and HR=0.104; p=0.850, respectively). Furthermore, the analysis was repeated dividing the population between patients with G3-4 ALT elevation during treatment vs. patients without such elevation. Again, hazard ratios for PFS and OS are not statistically significant (HR=0.791; p=0.309 and HR=0.930; p=0.810930, respectively). Finally, the analyses was repeated, splitting the population in patients with peak>15 ULN vs. patients with peak<15 ULN and one again no statistical significant differences were identified neither in terms of PFS (HR=0.821 p=0.227) neither in terms of OS (HR=0.927 p=0.463). Conclusions: Liver toxicity is a common event during treatment with trabectedin and does not affect outcome. These results should discourage the premature discontinuation of the drug due to the increase in liver enzymes.
RATIONALE AND METHODS OF THE PROSPECTIVE STUDY OF BIOMARKERS, SYMPTOM IMPROVEMENT AND VENTRICULAR REMODELING DURING ENTRESTO THERAPY FOR HEART FAILURE (PROVE-HF) STUDY
Authors: James L. Januzzi, Javed Butler, G. Michael Felker, Emmanuel Fombu, Alan Maisel, Kevin McCague, Ileana Pina, Margaret Prescott, Jerome Riebman, Scott Solomon
Journal: Journal of the American College of Cardiology (2017)
Poor prognostic factors of post-CNS recurrence survival in breast cancer patients.
Authors: Carlos Castaneda Altamirano, Henry Leonidas Gomez, Joseph A. Pinto, Luis Jesus Schwarz, C. E. Vigil, Carlos Vallejos
Journal: Journal of Clinical Oncology (2012)

2097 Background: Survival after the onset of metastases in the central nervous system is very short. However, some variables could indicate subsets of worse prognosis. Our aim was to determine the value of clinicopathological characteristics and prognostic scores in the post-SNC recurrence survival. Methods: We evaluated a retrospective cohort of 2597 breast cancer patients treated at the Instituto Nacional de Enfermedades Neoplasicas (Lima-Peru) between 2000-2005. Clinicopathological data was retrieved, RPA and GPA brain metastases prognostic scores were constructed and phenotypes were categorized according to the IHC expression in [HR+,HER2-], [Any HR, HER2+] and Triple Negative. Survival was calculated according to the Kaplan Meier methodology and cases were stratified by variables evaluated. The log-rank or Breslow tests were used when appropriate and multivariate analysis was done by the cox regression. A P&lt;0.05 was considered statistically significant. Results: One hundred and fifty seven cases developed CNS metastasis, from which 23 developed leptomeningeal metastases. The post recurrence CNS survival was 0.405 years. There were not differences according to phenotype (P=0.102), histological grade (P=0.647), number of brain metastases (P=0.695) and metastases volume (P=0.155). We found statistic differences in regard to leptomeningeal carcinomatosis (present, 0.249ys vs absent 0.436ys; P=0.033); CSF infiltration (present, 0.115ys vs absent, 1.044ys; P=0.022); status of primary tumor (controlled, 0.501ys vs uncontrolled, 0.263ys; P&lt;0.001); ECOG performance status (&lt;2, 0.504ys vs ≥2, 0.288ys; P=0.030); and time from BC diagnosis to SNC metastases (&lt;8 moths, 0.115 vs ≥8 months, 0.425ys; P=0.023). Cox regression identifies to CSF infiltration as statistically significant (HR=9.77; P=0.025). In regard to Prognostic scores, we found differences when cases were stratified according to RPA score (Class I, 0.564ys vs Class II, 0.455ys vs Class III, 0.288ys; P=0.049) and GPA score (0-1, 0.26ys vs 1.5-3, 0.455ys vs 3.5-5, 0,564; 0.048). Conclusions: RPA and GPA scores are more accurate to identify poor survival subsets in this group of patients than other tumor features (phenotype or histology).
Hospice utilization by men dying of prostate cancer
Authors: J. Bergman, C. S. Saigal, D. C. Miller, J. Hanley, J. L. Gore, K. Lorenz, M. S. Litwin
Journal: Journal of Clinical Oncology (2009)

9501 Background: The 25,000 American men who die of prostate cancer each year often suffer from fatigue, bone pain, and weight loss. Enrollment in hospice programs improves both the quality of life and the quality of death for this cohort. However, previous data suggest that hospice is often used inappropriately, either through underuse or through improperly timed referral. We sought to characterize sociodemographic and clinical factors that affect appropriate and inappropriate utilization of hospice services by men with metastatic prostate cancer in a population-based dataset. Methods: We used linked data from Surveillance, Epidemiology, and End Results and Medicare data to identify a cohort of beneficiaries who died of prostate cancer between 1992 and 2005. We then evaluated the bivariate association between sociodemographic and clinical data and any hospice enrollment. Hospice referrals within 7 days of death or more than 180 days before dying were considered inappropriate. Results: Of the 14,521 men dying of prostate cancer, 7,646 (53%) utilized hospice resources. Enrollment within 7 days of death was noted in 1699 subjects (22% of hospice users), and enrollment more than 180 days prior to death was seen in 717 participants (9% of hospice users). Subjects who utilized hospice within the appropriate time frame were enrolled for a mean of 47 days (S.D. 41, range 7–180 days) prior to death, with a median of 31 days. In our bivariate analysis, white ethnicity, partnered status, and achieving at least a high school diploma were significantly associated with hospice use ( Table ). Conclusions: Hospice utilization rates in our cohort compared favorably with previous analyses, but the frequency of improperly timed hospice referrals was similar to prior reports and provides an opportunity for improvement. [Table: see text] No significant financial relationships to disclose.
TF Independent Potentiation of FVIIa Activity in CAD Plasma: An Assessment Using Two Chromogenic Assays.
Authors: Vladimir Bogdanov, Giovanni Cimmino, Jonathan G Tardos, Brian G Choi, Annapoorna Kini, Samin K Sharma, Sharad Kothari, James R Tunstead, Sajiv Chandradas, Bjarne Østerud, Juan J Badimon
Journal: Blood (2008)
A Pilot Study of High-Dose N-Acetylcysteine Infusion in Patients with Sickle Cell Disease
Authors: Hasan Tahsin Ozpolat, Junmei Chen, Xiaoyun Fu, Shelby A Cate, Jennie Le, Minhua Ling, Colette Norby, Dominic W Chung, Barbara A. Konkle, Jose A. Lopez
Journal: Blood (2016)
IMPACT OF COMORBID CORONARY ARTERY DISEASE AND SEVERE PERIPHERAL ARTERY DISEASE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS
Authors: Windsor Ting, Qi Zhao, Lloyd Haskell, Fedor Lurie, Jeffrey Berger, Zubin Eapen, Matthew Valko, Veronica Alas, Kelly Rich, Concetta Crivera, Jeff Schein
Journal: Journal of the American College of Cardiology (2017)
HEMODYNAMICALLY-SUPPORTED PCI OF CHRONIC TOTAL OCCLUSIONS: A CASE SERIES
Authors: Robert Francis Riley, Sanjog Kalra, Mohamad Lazkani, Ashish Pershad, Ajay Kirtane, William Lombardi, Jeffrey Moses, James McCabe, Tony DeMartini, Dimitrios Karmpaliotis
Journal: Journal of the American College of Cardiology (2017)
PROVISIONAL VERSUS ELECTIVE TWO-STENTING STRATEGY FOR UNPROTECTED TRUE LEFT MAIN BIFURCATION LESIONS: A SUB-STUDY FROM FAILS 2 STUDY
Authors: Hiroyoshi Kawamoto, Alaide Chieffo, Richard Jabbour, Fabrizio D'Ascenzo, Enrico Cerrato, Fabrizio Ugo, Marco Pavani, Roberto di Summa, Ferdinando Varbella, Giacomo Boccuzzi, Pierluigi Omedè, Roberto Garbo, Federico Conrotto, Antonio Montefusco, Giuseppe Biondi-Zoccai, Maurizio D'Amico, Claudio Moretti, Javier Escaned, Fiorenzo Gaita, Sunao Nakamura, Antonio Colombo
Journal: Journal of the American College of Cardiology (2017)
Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment.
Authors: Nishant Tageja, Weixin Wang, Ryan Plyler, Meghan Corrigan-Cummins, Neha Korde, Elisabet E. Manasanch, Manisha Bhutani, Mary Kwok, Aaron W. Flanders, Diamond Zuchlinski, Marcia Mulquin, Rene Costello, Mark J. Roschewski, Ola Landgren, Katherine R. Calvo, Adriana Zingone
Journal: Journal of Clinical Oncology (2013)

8597 Background: Presently, there is no reliable biomarker for predicting clinical progression from smoldering (SMM) to symptomatic MM for individual patients. To improve our understanding on the pathogenesis from SMM to MM, we conducted a screening study of circulating cytokines using peripheral blood (PB) and bone marrow supernatant (BM) collected from treatment naïve SMM and MM patients as well as healthy donors as controls. Methods: PB samples from 14 SMM and 38 MM patients and 7 controls and BM obtained from 17 MM patients and 9 controls were assayed in duplicates using ultra-sensitive Human TH1/TH2 10-plex multi-spot plate and multi-array plate for interleukin-(IL)-6. Two-tailed Mann-Whitney test was used for statistical analysis. Results: PB of SMM patients (vs controls) had increased levels of several cytokines, including IL-8 (p=0.008) and IFN-gamma (p=0.002). In PB, MM patients (compared to SMM patient and controls) had increased levels of IL-6 (p=0.006 and 0.001, respectively), IL-8 (p=0.0001 and 0.008), IL-10 (p=0.02 and 0.02), TNF-alpha (p=0.01 and 0.009), and IFN-gamma (p=0.01 and 0.02). Analysis of BM revealed a similar profile with increased levels of IL-2, IL-6, IL-8, and TNF-alpha in MM patients compared with controls (p=0.007, p=0.0003, p=0.0001 and p=0.0008). Conclusions: We found significantly increased levels of key cytokines associated with progressive disease state (controls→SMM→MM). Patterns of cytokines were similar in BM and PB, suggesting that serum based cytokines may have a future role as biomarkers for disease progression, and could potentially be assessed as novel targets for treatment.
A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis
Authors: A.L. Henry, S.D. Kyle, A. Chisholm, C.E.M. Griffiths, C. Bundy
Journal: British Journal of Dermatology (2017)

Research suggests that sleep disturbance is common in psoriasis. While several sleep investigations have been conducted in psoriasis populations, many have methodological shortcomings, and no study has examined multiple dimensions of sleep-wake functioning. Moreover, research has yet to be performed comprehensively examining the range of physical and psychological factors that may affect sleep in people with psoriasis.To characterize sleep disturbance using validated measures and to identify physical and psychological predictors of sleep quality in people with psoriasis.An online survey was conducted (186 respondents; mean age 39·2 years) comprising validated measures assessing sleep [Pittsburgh Sleep; Quality Index (PSQI), Berlin Questionnaire, Pre-Sleep Arousal Scale]; chronotype (Morningness-Eveningness Questionnaire); mood (Hospital Anxiety and Depression Scale); itch (5-D Itch Scale); and psoriasis severity (Simplified Psoriasis Index). Group comparisons and regression analyses were used to examine predictors of poor sleep.The mean PSQI score was 9·2 ± 4·3, with 76·3% scoring above the threshold for poor sleep (≥ 6 on the PSQI) and 32·5% scoring 'positive' for probable obstructive sleep apnoea (OSA). Poor sleep and high likelihood of OSA were associated with more severe psoriasis (P < 0·05; η = 0·07; η2 = 0·005). Cognitive arousal (β = 0·26, P = 0·001), itch (β = 0·26, P < 0·001) and depression (β = 0·24, P = 0·001) were the most robust predictors of poor sleep quality, which, together with somatic arousal (β = 0·17, P = 0·022), accounted for 43% of variance in PSQI scores.Poor sleep is common in psoriasis and associated with psychological and physical factors. Rates of probable OSA are also high. Given the importance of restorative sleep for health, sleep complaints should receive greater clinical attention in the management of psoriasis.
DRENAJE ENDOSCOPICO O PERCUTANEO EN EL TRATAMIENTO DE ESTENOSIS NEOPLÁSICAS DEL HILIO HEPATICO
Authors: N Fernandez, G Molina, E Pinedo, L Vaquero, J Espinel
Journal: Endoscopy (2015)

Introducción: Las estenosis neoplásicas del hilio hepático abarcan: tumor de klatskin, cáncer de vesicular, tumores metastásicos y adenopatías. La tasa de resecabilidad quirúrgica es baja. El tratamiento paliativo pretende aliviar los síntomas y mejorar la calidad de vida de los pacientes. Las principales técnicas paliativas son: el drenaje endoscópico (DE) y el drenaje percutáneo (DP). Existe cierta controversia respecto a las ventajas e inconvenientes de cada uno de estos procedimientos paliativos.
THROMBOLYSIS IN CORONARY MICRO-CIRCULATION OCCLUSION BY DODECAFLUOROPENTANE ACOUSTIC VAPORIZABLE NANO-DROPLET WITH ULTRASOUND IRRADIATION
Authors: Bo Hu, Nan Jiang, Qing Zhou, Jin-Ling Chen, Sheng Cao, Jing-Jing Cui, Rui-Qiang Guo
Journal: Journal of the American College of Cardiology (2017)
Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis
Authors: Sung-Han Yoon, Sabine Bleiziffer, Ole De Backer, Victoria Delgado, Takahide Arai, Johannes Ziegelmueller, Marco Barbanti, Rahul Sharma, Gidon Y. Perlman, Omar K. Khalique, Erik W. Holy, Smriti Saraf, Florian Deuschl, Buntaro Fujita, Philipp Ruile, Franz-Josef Neumann, Gregor Pache, Masao Takahashi, Hidehiro Kaneko, Tobias Schmidt, Yohei Ohno, Niklas Schofer, William K.F. Kong, Edgar Tay, Daisuke Sugiyama, Hiroyuki Kawamori, Yoshio Maeno, Yigal Abramowitz, Tarun Chakravarty, Mamoo Nakamura, Shingo Kuwata, Gerald Yong, Hsien-Li Kao, Michael Lee, Hyo-Soo Kim, Thomas Modine, S. Chiu Wong, Francesco Bedgoni, Luca Testa, Emmanuel Teiger, Christian Butter, Stephan M. Ensminger, Ulrich Schaefer, Danny Dvir, Philipp Blanke, Jonathon Leipsic, Fabian Nietlispach, Mohamed Abdel-Wahab, Bernard Chevalier, Corrado Tamburino, David Hildick-Smith, Brian K. Whisenant, Seung-Jung Park, Antonio Colombo, Azeem Latib, Susheel K. Kodali, Jeroen J. Bax, Lars Søndergaard, John G. Webb, Thierry Lefèvre, Martin B. Leon, Raj Makkar
Journal: Journal of the American College of Cardiology (2017)

Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS).This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry.Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar baseline characteristics. Procedural and clinical outcomes were recorded according to Valve Academic Research Consortium-2 criteria.Compared with patients with tricuspid AS, patients with bicuspid AS had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and a significantly lower device success rate (85.3% vs. 91.4%; p = 0.002). Early-generation devices were implanted in 320 patients with bicuspid and 321 patients with tricuspid AS, whereas new-generation devices were implanted in 226 and 225 patients with bicuspid and tricuspid AS, respectively. Within the group receiving early-generation devices, bicuspid AS had more frequent aortic root injury (4.5% vs. 0.0%; p = 0.015) when receiving the balloon-expanding device, and moderate-to-severe paravalvular leak (19.4% vs. 10.5%; p = 0.02) when receiving the self-expanding device. Among patients with new-generation devices, however, procedural results were comparable across different prostheses. The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid AS (17.2% vs. 19.4%; p = 0.28).Compared with tricuspid AS, TAVR in bicuspid AS was associated with a similar prognosis, but lower device success rate. Procedural differences were observed in patients treated with the early-generation devices, whereas no differences were observed with the new-generation devices.
Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph<sup>+</sup> ALL) on Children’s Oncology Group AALL0622.
Authors: William Birdsall Slayton, John A Kairalla, Kirk R. Schultz, Meenakshi Devidas, Shanjun Helian, Michael Pulsipher, Bill H. Chang, William L. Carroll, Michael J. Borowitz, Valerie I. Brown, Naomi J. Winick, Andrew J Carroll, Nyla A. Heerema, Julie M Gastier-Foster, Brent L. Wood, Sherri L. Mizrahy, Stephen Hunger
Journal: Journal of Clinical Oncology (2015)

10006 Background: Children, adolescents and young adults with Ph+ALL treated on COG AALL0031 had an outstanding 70% 5-year disease-free survival (DFS) rate with intensive chemotherapy plus imatinib given continuously. We hypothesized that dasatinib would improve outcomes compared to imatinib due to increased potency, better CNS penetration, and activity against imatinib-resistant clones. Methods: AALL0622 tested the safety and feasibility of adding dasatinib 60 mg/m2 daily to AALL0031 chemotherapy in newly diagnosed Ph+ALL subjects (1-30 yrs). Cohort 1 subjects received dasatinib 2 wks out of each 3-4 wk block, whereas Cohort 2 subjects received dasatinib continuously. SCT was recommended for subjects with a sibling donor and those with high risk (HR) disease based on rate of response measured by flow cytometry at end induction and consolidation. The remaining standard risk (SR) subjects were treated with chemotherapy plus dasatinib. While all AALL0031 subjects received cranial XRT, only CNS3 cases on AALL0622 received the same. Results: Sixty eligible subjects were enrolled from 7/2008 to 2/2012 (39 Cohort 1 and 21 Cohort 2); 33 completed protocol therapy; 18 came off therapy to have SCT, 2 were inevaluable for cohort based analysis, and 7 were dropouts. Dasatinib plus chemo was well tolerated with no toxic deaths. For the 51 evaluable subjects, 3 yr event-free (EFS) and overall (OS) survival were 79±6% and 93±3%, respectively. SR subjects (n = 48, 19% underwent SCT) had a 3-yr EFS/OS of 83±6%/96±3% and HR subjects (n = 9, 78% underwent SCT) had an EFS/OS of 63±19%/88±13%. Ten percent (6/60) had an isolated or combined CNS relapse on AALL0622 vs 6% (3/54; p = 0.50) on AALL0031. No difference in DFS was seen between AALL0031 subjects receiving imatinib continuously and AALL0622 whole cohort (3-yr DFS of 79 ±6% for both studies, p = 0.39). Conclusions: Dasatinib with intensive chemotherapy was well tolerated. Subjects with rapid response had excellent outcomes without SCT. Further follow-up and additional trials are necessary to define the relative role of dasatinib and imatinib in promoting long-term survival in pediatric Ph+ ALL. Clinical trial information: NCT00720109.
IMPACT OF SEX ON PHYSICAL LIMITATION &amp; PATIENT HEALTH STATUS AFTER CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: PROPENSITY MATCHED SUBSTUDY OF OPEN-CTO REGISTRY
Authors: Divya Ratan Verma, John Spertus, Robert Yeh, William Lombardi, James Sapontis, James Grantham, Ashish Pershad
Journal: Journal of the American College of Cardiology (2017)
Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).
Authors: Christopher Flowers, Hilary Rosenthal, Jennifer Brown, Wendy Stock, Harvey Katzen, Shailendra Lakhanpal, David Jaye
Journal: Blood (2007)
IMPACT OF STATIN THERAPY ON COLLAGEN TURNOVER AND LEFT VENTRICLE FUNCTION AFTER ST-ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL
Authors: Thiago Quinaglia Silva, Simone Santos, José Carlos Silva, Osório Almeida, Joalbo Andrade, Eliana de Faria, Wilson Nadruz Junior, Orlando Petrucci, Sposito Andrei Carvalho
Journal: Journal of the American College of Cardiology (2017)
RELATIONSHIP BETWEEN DIASTOLIC BLOOD PRESSURE AND ALL-CAUSE MORTALITY WITH LOWER SYSTOLIC BLOOD PRESSURE AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE: LONG-TERM FOLLOW-UP OF THE US COHORT OF THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)
Authors: Anita Wokhlu, Yan Gong, Rhonda Cooper-DeHoff, Steven M. Smith, Eileen Handberg, Carl Pepine
Journal: Journal of the American College of Cardiology (2017)
CORONARY STEAL FROM A LEFT INTERNAL MAMMARY ARTERY BYPASS GRAFT VIA HIGH OUTPUT HEMODIALYSIS ARTERIOVENOUS FISTULA
Authors: Benjamin Horn, Parasuram Krishnamoorthy, Janani Rangaswami, Jon George, Napatt Kanjanahattakij, Pradhum Ram, Mario Naranjo, Kimberly Kochersperger Lessard
Journal: Journal of the American College of Cardiology (2017)
CARDIAC MYOSIN-BINDING PROTEIN C AS ALTERNATIVE TO CARDIAC TROPONIN T FOR THE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION IN THE VERY EARLY PHASE
Authors: Thomas Edward Kaier, Carsten Stengaard, Jack Marjot, Jacob Sorensen, Stavroula Stavropoulou-Tatla, Christian Terkelsen, Kristian Thygesen, Michael Marber, Hans Botker
Journal: Journal of the American College of Cardiology (2017)
Traitement endoscopique des fistules sur sleeve: quelle prise en charge aujourd'hui? Evaluation des pratiques dans un centre de référence
Authors: D Lorenzo, T Guilbaud, J Gonzalez, A Benezech, S Berdah, T Bège, M Barthet
Journal: Endoscopy (2017)

Les fistules après sleeve gastrectomie (SG) sont une complication majeure de la chirurgie bariatrique. La prise en charge endoscopique a évolué au fur et à mesure du temps passant d'une stratégie de fermeture des fistules (prothèse et clips) à une stratégie de drainage endocavitaire (drain nasokystique et prothèse double queue de cochon). L'objectif principal de cette étude était d'évaluer ces différentes stratégies de prise en charge.
CORONARY ARTERY BYPASS GRAFT SURGERY WITH OR WITHOUT LEFT ATRIAL APPENDAGE (LAA) EXCISION FOR ATRIAL FIBRILLATION : A CHA2DS2VASC MATCHED ANALYSIS OF THROMBOEMBOLIC OUTCOMES IN A NATIONAL DATABASE
Authors: Odunayo Olorunfemi, Ayman Elbadawi, Gbolahan Ogunbayo, Oladimeji Akinboro, Rebecca Ojo, Deola Saheed, Amole Ojo
Journal: Journal of the American College of Cardiology (2017)